期刊文献+

糖耐量低减患者的血管内皮生长因子及血清C反应蛋白水平分析

Analysis of serum levels of vascular endothelial growth factor and C-reactive protein in patients with impaired glucose tolerance
下载PDF
导出
摘要 目的探讨糖耐量低减患者血管内皮生长因子、血清C反应蛋白水平的变化。方法口服75 g葡萄糖耐量试验筛查出糖耐量低减患者61例和糖耐量正常的体检健康者30例,测定两组人群血清内皮生长因子、血清C反应蛋白水平。结果糖耐量低减组血管内皮生长因子、血清C反应蛋白水平均高于糖耐量正常组(P<0.01)。结论在糖耐量低减阶段,患者血管内皮生长因子、血清C反应蛋白已开始升高,提示糖耐量低减人群具备了发生血管并发症的危险。 Objective To investigate changes of serum levels of vascular endothelial growth factor (VEGF) and C-reactive protein (CRP) in patients with impaired glucose tolerance (IGT). Methods 61 patients with IGT (patient group) and 30 controls with normal glucose tolerance (NGT) (control group) diagnosed by oral glucose tolerance test (OGTT) were involved in the investigation. Serum levels of vascular endothelial growth factor (VEGF) and C-reactive protein (CRP) were measured for the two groups. Results The serum levels of VEGF and CRP in patients with IGT were both significantly higher than those in controls (P〈0. 01). Conclusion In the stage of impaired glucose tolerance, serum levels of VEGF and CRP begin to rise, indicating the population with IGT are susceptible to vascular complications.
作者 唐志浩 杨华
出处 《检验医学与临床》 CAS 2008年第11期660-661,共2页 Laboratory Medicine and Clinic
关键词 糖耐量低减 血管内皮生长因子 血清C反应蛋白 impaired glucose tolerance(IGT) vascular endothelial growth factor(VEGF) C-reactive protein (CRP)
  • 相关文献

参考文献4

  • 1贾茜,朱梅佳.胰岛素受体与VEGF[J].国际病理科学与临床杂志,2005,25(5):453-456. 被引量:3
  • 2[2]Nchoon KW,Naoyukio K,Jeanetse ME,et al.VEGF is major stimulator in model of choroidal neovas cularization[J].Intest Ophthalmol Vis Sci,2000,41(10):3158-3164.
  • 3[3]Lu M,Amano S,Miyamoto K,et al.Insulin induced vascular endothelial growth factor expression in retina[J].Invest Ophthalmol Vis Sci,1999,40(Ⅱ):3281-3286.
  • 4卢艳慧,陆菊明.糖耐量低减必需治疗[J].临床内科杂志,2006,23(2):141-143. 被引量:19

二级参考文献44

  • 1张翼飞,詹维伟,洪洁,顾卫琼,杨义生,桂明辉,唐金凤,王卫庆,刘建民,赵咏桔,宁光.糖耐量受损人群颈动脉内中膜厚度与各代谢指标的关系[J].中华糖尿病杂志(1006-6187),2005,13(1):23-26. 被引量:35
  • 2Pan XR,Li GW,Hu YH,et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care. 1997,20:537-544.
  • 3Tominaga M. Epidemiology on impaired glucose tolerance. Nippon Rinsho, 1996,54:2643-2648.
  • 4Tominaga M, Eguchi H, Manaka H ,et al. Impaired glucose toierance is a risk factor for cardiovascular disease, but not impaired fasting glucose.Diabetes Care, 1999,22:920-924.
  • 5Kim YZ,Kim C, Choi CS, et al. Microalbuminuria is associated with the insulin resistance syndrome independent of hypertension and type 2 diabetes in the Korean population. Diabetes Res Clin Pract ,2001,52 :145-152.
  • 6Tuomilehto J, Lindstrom J, Eriksson JG, et al. Finnish Diabetes Prevention Study Group, Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med,2001,344 : 1343-1350.
  • 7Knowler WC, Barrett-Connor E, Fowler SE, et al. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med, 2002,346:393-403.
  • 8Chiasson JL, Josse RG, Gomis R,et al. STOP-NIDDM Trail Research Group. Acarbose for prevention of type 2 diabetes mellitus : the STOP-NIDDM randomised trial. Lancet, 2002,359:2072-2077.
  • 9Chiasson JL, Josse RG, Gomis R, et al. TOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA ,2003,290:486-494.
  • 10Hanefeld M, Chiasson JL, Koehler C, et al. Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance. Stroke,2004,35 : 1073-1078.

共引文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部